🚨 TOMORROW IN SINGAPORE: From Phase 1 Straight to Patients? Biotechs face a catch-22: they need money to collect clinical data, but need data to raise money. Even after Phase 1, years may separate a treatment from patients—and some firms die in this “valley of death”. Montana’s SB535 creates another route. Eligible post-Phase-1 treatments may be offered at state-licensed treatment centres after independent review. This is not FDA approval, but it could enable earlier access while generating evidence. Tomorrow, Niklas Anzinger (Infinita founder & CEO) & Stephen Martin (Infinita U.S. Lead; Montana Experimental Treatment Review Board (METRB) Operations Lead) will explain how it works & how SG biotechs could use it. 📅 Mon, 26 Oct | 4–6 pm 📍 Draper at The Working Capitol, 39 Ann Siang Rd 🥤 Light refreshments provided 🎥 Watch the explainer on Montana’s SB535 here 🔗 Register here 🎆 Join this channel for longevity meet-ups, competitions & career opportunities in Singapore 👉 https://t.me/cureaging